When applied to epilepsy, NMR-based metabolomics can help uncover specific biochemical patterns associated with disease state and seizure activity, potentially facilitating better diagnostic and therapeutic strategies
Furthermore, GLP-1 medications have been linked to cardiovascular benefits, making them a multifaceted option for patients who may also be at risk for heart disease
As we navigate our health journeys together, embracing a personalized approach to weight loss and diabetes management is vital
Approval status is night and day: tirzepatide is FDA-approved (Mounjaro in 2022, Zepbound in 2023), while retatrutide is still working through Phase 3
In contrast, the introduction of a monoclonal somatostatin antibody resulted in only partial inhibition [50, 51]